• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Frontiers in Public Health >Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature
【24h】

Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature

机译：低收入和中等收入国家的抗癌药物的可用性，负担能力，访问和定价：对文学的系统审查

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Cancer is the second leading cause of death globally accounting for more than half of deaths in Low- and Middle-Income Countries (LMICs). Cancer treatment is expensive and the high prices of cancer medicines have a huge impact on access in LMICs. Scarcity of pricing or affordability data is one of the major barriers in the development of effective and transparent pricing policies in LMICs. This study aimed to conduct a systematic review of the literature regarding pricing, availability, affordability, and access to anti-cancer medicines in LMICs. Method: A systematic search was conducted across six electronic databases: PubMed, Medline/CINAHL (EBSCO), Web of Science, Springer Links, Scopus, and Google Scholar. The literature (from 2015 to 2020) was reviewed to identify original research articles published in English. Results: A total of 13 studies were included in the review with some having multiple outcomes: five studies on pricing, four studies addressed affordability, five studies reported on availability, and four studies on access to anti-cancer medicines. The studies showed that in LMICs, there are wide variations in cancer prices and availability amongst the medicine brands and across different countries, with less affordability by patients with low-income levels, sometimes leading to treatment abandonment. Conclusion: Given the importance of medicine availability and prices in patient access and medicine buying capacity of governments, multi-pronged policy and program approaches by multiple stakeholders are needed to ensure access to cancer medicines.
机译：背景：癌症是第二次死亡原因全球占低收入和中等收入国家死亡人数的一半以上（LMIC）。癌症治疗昂贵，癌症药物的高价格对LMIC的访问产生了巨大影响。定价或负担能力数据的稀缺是在LMIC中发展有效和透明定价政策的主要障碍之一。本研究旨在对液化物质中的定价，可用性，负担能力和抗癌药物进行系统审查。方法：在六个电子数据库中进行系统搜索：PubMed，Medline / Cinahl（EBSCO），科学网站，Springer Links，Scopus和Google Scholar。该文献（从2015年到2020年）被审查以确定以英语发表的原始研究文章。结果：审查中共有13项研究，其中一些具有多种结果：五项研究，四项研究涉及可负担性，五项研究报告可用性，并进行了四项研究进入抗癌药物的研究。研究表明，在LMIC中，药物品牌和不同国家的癌症价格和可用性有广泛的癌症价格和可用性，低收入水平患者的负担性较少，有时导致遗弃遗弃。结论：鉴于医学可用性和价格在患者存取和药物购买能力的重要性，需要多时间政策和方案方法，以确保获得癌症药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号